| Q42945648 | 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial |
| Q48420736 | Advances in molecular imaging for the diagnosis of dementia |
| Q52644592 | Amsterdam Dementia Cohort: Performing Research to Optimize Care. |
| Q48254113 | Amyloid and its association with default network integrity in Alzheimer's disease |
| Q48533050 | Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement |
| Q37897691 | Amyloid imaging |
| Q35029095 | Amyloid imaging and memory change for prediction of cognitive impairment |
| Q35600979 | Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia |
| Q24648007 | Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo |
| Q39182933 | Amyloid imaging in prodromal Alzheimer's disease |
| Q57471615 | Assessing Amyloid Pathology in Cognitively Normal Subjects using [F]Flutemetamol PET: Comparing Visual Reads and Quantitative Methods |
| Q28264556 | Beta-amyloid deposition and the aging brain |
| Q50778486 | Blood-brain barrier P-glycoprotein function in Alzheimer's disease. |
| Q34102331 | Brain imaging in the study of Alzheimer's disease |
| Q33800668 | Brain microbleeds and Alzheimer's disease: innocent observation or key player? |
| Q29397707 | Clinical amyloid imaging in Alzheimer's disease |
| Q37466301 | Clinical applications of PET amyloid imaging: an update. |
| Q53172274 | Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings. |
| Q37456054 | Does Alzheimer's disease begin in the brainstem? |
| Q37394202 | FDDNP binding using MR derived cortical surface maps. |
| Q33479675 | Imaging in Alzheimer's disease |
| Q33790277 | In vivo human amyloid imaging |
| Q34776816 | Is there a neuropathology difference between mild cognitive impairment and dementia? |
| Q33419936 | Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data |
| Q50764182 | Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. |
| Q36662808 | Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients |
| Q33899600 | Mapping brain beta-amyloid |
| Q93242548 | Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers |
| Q92225367 | Optical coherence tomography angiography in preclinical Alzheimer's disease |
| Q34725521 | Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain |
| Q37596431 | Quantitative evaluation of Alzheimer's disease |
| Q36164757 | Quantitative multimodal multiparametric imaging in Alzheimer's disease |
| Q91781268 | Retinal layer thickness in preclinical Alzheimer's disease |
| Q34754658 | Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment |
| Q28253740 | Tau imaging: early progress and future directions |
| Q37378270 | Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease |
| Q37029599 | The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease |
| Q38001577 | The prognostic value of amyloid imaging. |
| Q37688880 | The use of PET in Alzheimer disease |
| Q40983810 | Unirhinal Olfactory Testing for the Diagnostic Workup of Mild Cognitive Impairment |
| Q36526176 | Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta |
| Q35131160 | [F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment. |